Mustang Bio Inc (NASDAQ: MBIO) has experienced a rise in its stock price by 11.36 compared to its previous closing price of 1.29. However, the company has seen a gain of 2.13% in its stock price over the last five trading days. globenewswire.com reported 2025-03-05 that WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement as required by Nasdaq Listing Rule 5550(b)(1).
Is It Worth Investing in Mustang Bio Inc (NASDAQ: MBIO) Right Now?
Company’s 36-month beta value is 2.26.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MBIO is 1.59M, and currently, short sellers hold a 2.77% ratio of that floaft. The average trading volume of MBIO on April 03, 2025 was 338.84K shares.
MBIO’s Market Performance
MBIO’s stock has seen a 2.13% increase for the week, with a -11.11% drop in the past month and a -84.52% fall in the past quarter. The volatility ratio for the week is 10.13%, and the volatility levels for the past 30 days are at 9.89% for Mustang Bio Inc The simple moving average for the past 20 days is 1.40% for MBIO’s stock, with a -87.26% simple moving average for the past 200 days.
Analysts’ Opinion of MBIO
Many brokerage firms have already submitted their reports for MBIO stocks, with BTIG Research repeating the rating for MBIO by listing it as a “Buy.” The predicted price for MBIO in the upcoming period, according to BTIG Research is $11 based on the research report published on May 18, 2021 of the previous year 2021.
B. Riley FBR, on the other hand, stated in their research note that they expect to see MBIO reach a price target of $9. The rating they have provided for MBIO stocks is “Buy” according to the report published on October 02nd, 2020.
Cantor Fitzgerald gave a rating of “Overweight” to MBIO, setting the target price at $7 in the report published on November 20th of the previous year.
MBIO Trading at -41.89% from the 50-Day Moving Average
After a stumble in the market that brought MBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.78% of loss for the given period.
Volatility was left at 9.89%, however, over the last 30 days, the volatility rate increased by 10.13%, as shares sank -15.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -66.74% lower at present.
During the last 5 trading sessions, MBIO rose by +2.13%, which changed the moving average for the period of 200-days by -78.73% in comparison to the 20-day moving average, which settled at $1.4202. In addition, Mustang Bio Inc saw -83.73% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for MBIO
Current profitability levels for the company are sitting at:
- -8.36 for the present operating margin
- 0.53 for the gross margin
The net margin for Mustang Bio Inc stands at -8.12. The total capital return value is set at 3.07. Equity return is now at value -1191.31, with -116.47 for asset returns.
Based on Mustang Bio Inc (MBIO), the company’s capital structure generated -0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -16.95. The debt to equity ratio resting at -0.11. The interest coverage ratio of the stock is -6021.0.
Currently, EBITDA for the company is -16.25 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of 0.77. The receivables turnover for the company is 12.16for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.68.
Conclusion
In a nutshell, Mustang Bio Inc (MBIO) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
